The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical research

One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with <i>de novo</i> native coronary artery lesions: the SPIRIT II study

EuroInterv.2007;3:315-320.

1. Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand; 2. Amper kliniken AG, Klinikum Dachau, Dachau, Germany; 3. A.Z. Middelheim, Antwerpen, Belgium; 4. Aalborg Sygehus Syd, Aalborg, Denmark; 5. Isala Klinieken, Zwolle, The

Aims: The SPIRIT II study randomised 300 patients in a ratio of 3:1 to receive either a XIENCE V or a TAXUS stent. The six month clinical and angiographic results have previously been repor

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry